Drugs classes such as the Angiotensin Receptor-Neprilysin inhibitors (ARNi) and Sodium-Glucose co-Transporter-2 inhibitors (SGLT2i) demonstrated meaningfully improved outcomes, including survival and reduced HF hospitalizations (McMurray et al., 2014; Lee et al., 2019; Packer et al., 2020).Soluble guanylate-cyclase inhibitors and myosin activators led to significant, yet less impressive results (Armstrong et al., 2020; Teerlink et al., 2021). This evidence concerns the gene MYH14 and hydrops fetalis.